Evidence indicates an elevated risk of type 2 diabetes mellitus after breast cancer treatment, particularly for endocrine therapy. This Review outlines the evidence for adverse metabolic effects of endocrine therapies in humans. Potential mechanisms, informed by preclinical research, for the increased risk of type 2 diabetes mellitus are discussed.
- Nisha S. Thomas
- Rebecca L. Scalzo
- Elizabeth A. Wellberg